Casselini, Carolina M.
Parson, Henri K.
Frizzi, Katie E.
Marquez, Alex
Smith, Darrell R.
Guernsey, Lucie
Nemmani, Rakesh
Tayarani, Alireza
Jolivalt, Corinne G. http://orcid.org/0000-0003-4391-1341
Weaver, Jessica
Fernyhough, Paul
Vinik, Aaron I.
Calcutt, Nigel A.
Clinical trials referenced in this document:
Documents that mention this clinical trial
A muscarinic receptor antagonist reverses multiple indices of diabetic peripheral neuropathy: preclinical and clinical studies using oxybutynin
https://doi.org/10.1007/s00401-024-02710-4
Funding for this research was provided by:
national Institute of health (DK102032)
Article History
Received: 15 December 2023
Revised: 16 February 2024
Accepted: 17 February 2024
First Online: 25 March 2024
Declarations
:
: NAC and PF are co-founders of, and hold equity in WinSanTor Inc., a company which is developing products related to the research described in this paper. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. The other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.